Loading…
NewSelf Limited was cited for misbranding violations involving compounded semaglutide and tirzepatide products sold through its website under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act. The company falsely represented itself as the compounder of these drugs when it was not, and made misleading claims suggesting the compounded products were FDA-approved or evaluated for safety and effectiveness by referencing FDA-approved branded drugs like Ozempic®, Wegovy®, Mounjaro®, and Zepbound®. These violations resulted in the products being introduced into interstate commerce in violation of section 301(a) of the FDCA.